Vaccine Info

mRNA-1010 Quadrivalent Influenza Vaccine

Authored by
Staff
Last reviewed
July 10, 2021
Share

mRNA-1010 Quadrivalent Influenza Vaccine Description

Moderna, Inc.'s mRNA-1010 Quadrivalent Influenza Vaccine is Moderna's influenza vaccine candidate targeting WHO recommendations, including A H1N1, H3N2, and influenza B Yamagata and Victoria lineages. 

mRNA-1010 is Moderna’s first seasonal influenza vaccine candidate to enter the clinic, says the company. mRNA medicines take advantage of normal biological processes to express proteins and create a desired therapeutic effect. This enables the potential treatment of a broad spectrum of diseases, many of which cannot be addressed with current technologies.

“We expect that our seasonal influenza vaccine candidates will be an important component of our future combination respiratory vaccines,” said Stéphane Bancel, CEO of Moderna, on July 7, 2021. “Our vision is to develop an mRNA combination vaccine so that people can get one shot each fall for high efficacy protection against the most problematic respiratory viruses."

Cambridge, MA-based Moderna’s mRNA vaccine technology offers potential advantages in efficacy, speed of development, and production scalability and reliability, which may position the company as a leader in preparing for and responding to infectious disease threats that place millions of people at risk around the world. There are currently nine prophylactic mRNA vaccines in our development pipeline, with seven Phase 1 studies underway. To learn more, visit www.modernatx.com.

mRNA-1010 Quadrivalent Influenza Vaccine Indication

mRNA-1010 Quadrivalent Influenza Vaccine is indicated to prevent seasonal influenza.

mRNA-1010 Quadrivalent Influenza Vaccine News

July 7, 2021 - Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine. This Phase 1/2 randomized, stratified, observer-blind, dose-ranging study will evaluate the safety, reactogenicity, and immunogenicity of mRNA-1010, Moderna’s seasonal influenza vaccine candidate, in healthy adults 18 years and older in the U.S. The Company intends to enroll approximately 180 participants in the study. mRNA-1010 is Moderna’s first seasonal influenza vaccine candidate to enter the clinic. It targets lineages recommended by the World Health Organization (WHO) to prevent influenza, including seasonal influenza A H1N1, H3N2, and influenza B Yamagata and Victoria.

January 11, 2021 - Moderna, Inc. revealed in a press release influenza vaccine candidates (mRNA-1010, mRNA-1020, mRNA-1030). This first-generation flu program will evaluate multiple candidates comprising multiple antigen combinations against the 4 seasonal viruses recommended by the WHO. Phase 1 clinical trials for the program are expected to begin in 2021.

mRNA-1010 Quadrivalent Influenza Vaccine Clinical Trial

This Phase 1/2 randomized, stratified, observer-blind, dose-ranging study will evaluate the safety, reactogenicity, and immunogenicity of mRNA-1010, Moderna’s seasonal influenza vaccine candidate, in healthy adults 18 years and older in the U.S. The Company intends to enroll approximately 180 participants in the study.

Clinical Trials

No clinical trials found